Author:
Bourbon Estelle,Alcazer Vincent,Cheli Estelle,Huet Sarah,Sujobert Pierre
Abstract
The analysis of circulating tumor DNA (ctDNA) released by tumor cells holds great promise for patients with lymphoma, to refine the diagnostic procedure, clarify the prognosis, monitor the response to treatment, and detect relapses earlier. One of the main challenges of the coming years is to adapt techniques from highly specialized translational teams to routine laboratories as this requires a careful technical and clinical validation, and we have to achieve this as fast as possible to transform a promising biomarker into a routine analysis to have a direct consequence on patient care. Whatever the analytical technology used, the prerequisite is to obtain high yields of ctDNA of optimal quality. In this review, we propose a step-by-step description of the preanalytical process to obtain high-quality ctDNA, emphasizing the technical choices that need to be made and the experimental data that can support these choices.
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Reference48 articles.
1. Nuclear Acids In Human Blood Plasma;Mandel;C. R. Seances Soc. Biol. Fil.,1948
2. DNA Fragments in the Blood Plasma of Cancer Patients: Quantitations and Evidence for Their Origin from Apoptotic and Necrotic Cells;Jahr;Cancer Res.,2001
3. About the possible origin and mechanism of circulating DNA
4. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
5. The emerging role of cell-free DNA as a molecular marker for cancer management
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献